23 terminated, 17 recruiting, 12 completed, 9 active not recruiting. 67 Phase 2, 34 Phase 1, 1 Phase 3.
Follow Genmab: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Randomized Phase 2 Study Of Epcoritamab Vs Watch And Wait InPatients With Previously Untreated Low Tumor Burden FollicularLymphoma Epcoritamab, Observation - Randomized, Phase 2 | Phase 2 | Not yet recruiting | M.D. Anderson Cancer Center | 40 | 2027-02-12 | 2026-11-02 |
| Epcoritamab as Consolidation Therapy for High-Risk Pts w/CLL on BTKI Epcoritamab - CLL, CLL (Chronic Lymphocytic Leukemia) | Phase 2 | Not yet recruiting | University of California, Irvine | 24 | 2026-12-01 | 2026-11-09 |
| Study to Assess the Efficacy and Safety of Rina-S in Participants With Advanced Gastrointestinal (GI) Cancers Rina-S - Gastrointestinal Cancers | Phase 2 | Recruiting | Genmab | 160 | 2026-05-11 | 2026-11-03 |
| Study to Investigate Petosemtamab in Adults With Metastatic Non-Small Cell Lung Cancer Petosemtamab + Pembrolizumab - Lung Cancer - Non Small Cell Squamous, Lung Cancer - Non Small Cell Non-Squamous | Phase 2 | Withdrawn | Genmab | 2026-03-27 | 2026-11-02 | |
| Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer Rina-S - Non-small Cell Lung Cancer (NSCLC) | Phase 2 | Recruiting | Genmab | 240 | 2026-01-30 | 2026-11-03 |
| Epcoritamab in Combination With Loncastuximab Tesirine in Relapsed/Refractory Large B-cell Lymphoma Epcoritamab, Loncastuximab Tesirine - Large B-cell Lymphoma, Relapse | Phase 2 | Recruiting | University of Miami | 26 | 2026-01-07 | 2026-10-15 |
| Epcoritamab in Patients With Newly Diagnosed Marginal Zone Lymphoma (MZL) Epcoritamab - Marginal Zone Lymphoma, Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | Phase 2 | Recruiting | Izidore Lossos, MD | 25 | 2025-10-13 | 2026-10-15 |
| Study of Epcoritamab as a Consolidation Therapy in CLL/SLL Epcoritamab - CLL/SLL, CLL | Phase 2 | Recruiting | Zulfa Omer | 22 | 2025-08-22 | 2026-01-06 |
| A Study of Epcoritamab With Lenalidomide and Tafasitamab in People With Diffuse Large B Cell Lymphoma Epcoritamab, Lenalidomide, Tafasitamab - Lymphoma | Phase 2 | Withdrawn | Memorial Sloan Kettering Cancer Center | 2025-08-13 | 2026-04-07 | |
| Study of the Effectiveness and Safety of Acasunlimab Alone and With Pembrolizumab to Treat Advanced Melanoma of the Skin That Has Returned After Treatment With an Approved Checkpoint Inhibitor Therapy (ABBIL1TY MELANOMA-07) Acasunlimab, Pembrolizumab - Cutaneous Melanoma, Relapsed/Refractory, Locally Advanced Unresectable Melanoma (Stage IIIB, IIIC, or IIID) | Phase 2 | Terminated | Genmab | 1 | 2025-07-25 | 2026-09-30 |
| A Clinical Study to Test if an Investigational Treatment Called BNT314 When Used in Combination With Another Investigational Treatment Pumitamig (BNT327) and Chemotherapy, is Beneficial and Safe for Patients With Advanced Colorectal Cancer BNT314, Pumitamig, SoC chemotherapy treatment 1 - Metastatic Colorectal Cancer | Phase 1 / Phase 2 | Recruiting | BioNTech SE | 482 | 2025-07-18 | 2026-07-01 |
| Outpatient Epcoritamab in Large B-cell Lymphoma Epcoritamab, Rituximab combined with cyclophosphamide, vincristine, and prednisone, Rituximab combined with cyclophosphamide, doxorubicin, vincristine, and prednisone - Relapsed Large B-cell Lymphoma, Refractory Large B-cell Lymphoma | Phase 2 | Recruiting | Massachusetts General Hospital | 40 | 2025-06-05 | 2026-08-13 |
| Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Grade 3b Follicular Lymphoma | Phase 1 / Phase 2 | Recruiting | Yazeed Sawalha | 38 | 2025-04-02 | 2026-08-25 |
| A First-in-Human Trial of Safety and Efficacy of GEN1078 in Participants With Solid Tumors GEN1078 - Malignant Solid Tumor | Phase 1 / Phase 2 | Terminated | Genmab | 3 | 2025-01-29 | 2026-01-30 |
| Epco, Zanu, Ritux for R/R FL or MZL Zanubrutinib, Rituximab, Epcoritamab - Follicular Lymphoma, Lymphoma | Phase 2 | Recruiting | Reid Merryman, MD | 71 | 2025-01-21 | 2026-09-25 |
| Epcoritamab in Previously Treated WM Epcoritamab - Waldenstrom Macroglobulinemia, B-Cell Lymphoproliferative Disorder | Phase 2 | Recruiting | Gottfried von Keudell, MD PhD | 20 | 2024-12-06 | 2026-03-13 |
| A Phase 2 Study of Epcoritamab in Patients With Follicular Lymphoma and Marginal Zone Lymphoma Not Accomplishing a Complete Response With Upfront Therapy Epcoritamab - Lymphoma, Follicular Lymphoma | Phase 2 | Recruiting | Beth Israel Deaconess Medical Center | 35 | 2024-11-20 | 2026-11-12 |
| A Phase 1/2 Study of GEN1286 in Patients With Advanced Solid Tumors GEN1286 - Advanced Solid Tumor | Phase 1 / Phase 2 | Terminated | Genmab | 23 | 2024-11-13 | 2026-07-13 |
| Epcoritamab-CAR T Cells for Large B-cell Lymphomas Epcoritamab - Lymphoma, Non-Hodgkin, Relapsed Diffuse Large B Cell Lymphoma | Phase 2 | Recruiting | Abramson Cancer Center at Penn Medicine | 31 | 2024-09-24 | 2026-05-27 |
| Trial to Assess the Safety and Preliminary Efficacy of GEN1055 on Malignant Solid Tumors as Monotherapy and as Combination Therapy GEN1055, Pembrolizumab, Standard Chemotherapy - Malignant Solid Tumor | Phase 1 / Phase 2 | Terminated | Genmab | 21 | 2024-05-14 | 2026-08-11 |
Showing 20 of 67. Sign in to see all of them.
Carcinoma, Non-Small-Cell Lung (12) · Lymphoma, Large B-Cell, Diffuse (11) · Lymphoma, Follicular (8) · Ovarian Neoplasms (8) · Squamous Cell Carcinoma of Head and Neck (8) · Uterine Cervical Neoplasms (8) · Endometrial Neoplasms (7) · Lymphoma, Non-Hodgkin (7) · Colorectal Neoplasms (6) · Head and Neck Neoplasms (6) · Leukemia, Lymphocytic, Chronic, B-Cell (6) · Lymphoma (6) · Recurrence (6) · Esophageal Neoplasms (5) · Lymphoma, B-Cell, Marginal Zone (5)
pembrolizumab (12) · Lenalidomide (8) · Rituximab (8) · tisotumab vedotin (8) · zalutumumab (8) · Cyclophosphamide (7) · Doxorubicin (7) · Prednisone (7) · Vincristine (6) · Carboplatin (5) · Bevacizumab (3) · Cisplatin (3) · Gemcitabine (3) · Radiotherapy (3) · zanolimumab (3)
United States (55) · Spain (27) · United Kingdom (21) · Belgium (20) · Denmark (18) · France (18) · Italy (17) · Netherlands (16) · Germany (13) · South Korea (10) · Czechia (9) · Australia (8) · Japan (8) · Poland (8) · Sweden (8)
Johann de Bono, Professor (2) · Reid Merryman, MD (2) · Catherine C Coombs, MD (1) · Dai Chihara, MD (1) · Elise Chong, MD (1) · Gottfried von Keudell, MD (1) · Gottfried von Keudell, MD, PhD (1) · Hassan Aladdin, ICTM (1) · Ignace Vergote, Professor (1) · Izidore Lossos, MD (1) · Jean-Pascal Machiels, MD, PhD (1) · Juan Alderuccio, MD (1)
PMID 41044356, PMID 37496366, PMID 42411504, PMID 42541678, PMID 17602769, PMID 24714973, PMID 30745090, PMID 31796521, PMID 33845034, PMID 34508654, PMID 35176764, PMID 35633184, PMID 35688554, PMID 36548927, PMID 37651655, PMID 38151388, PMID 38528445, PMID 38889737, PMID 39322711, PMID 39792928, PMID 40319227, PMID 40347227, PMID 40472301, PMID 40550489, PMID 40632620, PMID 40920572, PMID 41380698, PMID 41784015, PMID 42000372, PMID 42285113, PMID 42431612, PMID 42622258, PMID 42660129
2023 (12), 2017 (4), 2025 (4), 2018 (2), 2019 (2), 2016 (1)